Индуцированный инфликсимабом волчаночно-подобный синдром у больной ревматоидным артритом (описание случая): случайность или закономерность?

Индуцированный инфликсимабом волчаночно-подобный синдром у больной ревматоидным артритом (описание случая): случайность или закономерность?

Автор: Муравьев Ю.В., Лебедева В.В., Аламанкина С.Ю.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Клинические наблюдения

Статья в выпуске: 4 т.55, 2017 года.

Бесплатный доступ

В статье описывается случай развития волчаночно-подобного синдрома, индуцированного инфликсимабом, у больной ревматоидным артритом, с обсуждением возможных причин возникновения такой патологии.

Ревматоидный артрит, инфликсимаб, волчаночно-подобный синдром

Короткий адрес: https://sciup.org/14945845

IDR: 14945845   |   DOI: 10.14412/1995-4484-2017-446-448

Список литературы Индуцированный инфликсимабом волчаночно-подобный синдром у больной ревматоидным артритом (описание случая): случайность или закономерность?

  • Wetter DA, Davis MDP. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc. 2009 Nov;84(11):979-84 DOI: 10.1016/S0025-6196(11)60668-X
  • Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-90 DOI: 10.1016/j.berh.2006.06.002
  • Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph. 1945;51:190-2 DOI: 10.1001/archderm.1945.01510210032007
  • Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82 DOI: 10.1196/annals.1422.019
  • Vasoo S. Drug-induced Lupus: an update. Lupus. 2006;15:757-61 DOI: 10.1177/0961203306070000
  • Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7 DOI: 10.1002/art.1780251101
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725 DOI: 10.1002/art.1780400928
  • Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716-20. /kep080 DOI: 10.1093/rheumatology
  • Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-90. doi: 10.1002/1529-0131(200011)43:113.0.CO;2-D
  • Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced Lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11:753-5 DOI: 10.1191/0961203302lu236cr
  • Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37:381-7 DOI: 10.1016/j.semarthrit.2007.08.003
  • Klapman JB, Ene-Stroscu D, Becker MA, Hanauer SB. A lupuslike syndrome associated with infiximab therapy. Inflamm Bowel Dis. 2003;9:176-8 DOI: 10.1097/00054725-200305000-00005
  • Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-7 DOI: 10.1016/S1590-8658(03)00448-1
  • Bleumink GS, ter Borg EJ, Ramselaar CG, Strickler BH. Etanercept-induced subacute cutaneous lupus erythemaotosus. Rheumatology. 2001;40:1317-9 DOI: 10.1093/rheumatology/40.11.1317
  • Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80 DOI: 10.1016/S0140-6736(02)07714-0
  • Carlson E, Rothfield N. Etanercept-induced lupus like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-6 DOI: 10.1002/art.11033
  • Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-2 DOI: 10.1136/ard.61.11.1031
  • Swale VJ, Perrett CM, Denton CP, et al. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-7 DOI: 10.1046/j.1365-2230.2003.01411.x
  • Kang M-J, Lee Y-H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-9 DOI: 10.3346/jkms.2006.21.5.946
  • Haake H, Käneke J, Amann K, et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin. 2007;102:852-7 DOI: 10.1007/s00063-007-1104-6
  • Van Rijthoven AWAM, Bijlsma JWJ, Canninga-Van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a preexisting anti-dsDNA antibody level. Rheumatology. 2006;45:1317- DOI: 10.1093/rheumatology/kel227
  • Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA)in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-94 DOI: 10.1136/ard.2005.043166
  • De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French survey. Arthritis Res Ther. 2005;7(3):R545-51 DOI: 10.1186/ar1715
  • Ramos-Casal M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies. Analysis of 233 cases. Medicine. 2007;86:242-51 DOI: 10.1097/MD.0b013e3181441a68
  • Thornhill J, Watson KD, Lord PA, et al. Drug-induced lupus in patients with inflammatory arthritis treated with TNF blocking agents: results from the BSR Biologics Register. BSR Abstracts. 2008.
  • Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in urine autoimmune 'lupus' nephritis. Nature. 1988;331:356-8 DOI: 10.1038/331356a0
  • Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumour necrosis factor. Eur J Immunol. 2000;30:2038-47. doi: 10.1002/1521-4141(200007)30:73.0.CO;2-K
  • Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumour necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989;52:421- DOI: 10.1016/0090-1229(89)90157-8
  • Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999;20:147-61 DOI: 10.1007/BF02786470
  • Romagnani S.Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285-94 DOI: 10.1097/00054725-199911000-00009
  • Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents anti-nuclear autoimmunity. Nat Med. 1999;5:694-7. doi: 10.1038/9544
  • Lorenz HM, Herrmann M, Winkler T, et al. Role of Apoptosis in autoimmunity. Apoptosis. 2000;5:443-9 DOI: 10.1023/A:1009692902805
  • Erikkson C, Engstrand S, Sundqvist K-G, Rantapaat-Dahlqvist S. Autoantibody formationin patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005;64:403-7 DOI: 10.1136/ard.2004.024182
  • Zheng L, Fisher G, Miller R, et al. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 1995;377:348-51 DOI: 10.1038/377348a0
  • Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-18 DOI: 10.1080/08916930500285857
  • D'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-а antibodies. J Intern Med. 2004;255:409-18 DOI: 10.1111/j.1365-2796.2003.01298.x
  • Benucci M, Saviola G, Baiardi P, et al. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNF blocking agents in rheumatoid arthritis. Clin Rheumatol. 2008;27:91-5 DOI: 10.1007/s10067-007-0728-5
Еще
Статья научная
SciUp 2024 © 2024 ©